National Strategy for the COVID-19 Response
Jan 23, 2021 20:51:16 GMT
miamianne67 and icemandios like this
Post by c2crusher on Jan 23, 2021 20:51:16 GMT
National Strategy for the COVID-19 Response
and Pandemic Preparedness
January 21, 2021
www.google.com/imgres?imgurl=https%3A%2F%2Fnlminfocusdotcom.files.wordpress.com%2F2014%2F11%2F761-fauci_schinazi.jpg%3Fw%3D700&imgrefurl=https%3A%2F%2Finfocus.nlm.nih.gov%2F2013%2F11%2F01%2Fcelebrating_public_service_at%2F&tbnid=aoztRpTDMyshIM&vet=12ahUKEwih7r7y9rLuAhVF66wKHQ-FBjEQMygAegQIARAZ..i&docid=x93Ncg9e3APY8M&w=250&h=209&q=Dr%20fauci%20and%20Dr%20Ray%20Schinazi&ved=2ahUKEwih7r7y9rLuAhVF66wKHQ-FBjEQMygAegQIARAZ
Raymond F. Schinazi, PhD, ScD (right) and Anthony S. Fauci, MD
Note: Very good chance COCP will be a very big part of this IMHO
www.whitehouse.gov/wp-content/uploads/2021/01/National-Strategy-for-the-COVID-19-Response-and-Pandemic-Preparedness.pdf
Prioritize therapeutics and establish a comprehensive, integrated
COVID-19 treatment discovery and development program.
Effective
treatments for COVID-19 are critical to saving lives. The federal government will
establish a comprehensive, integrated, and coordinated preclinical drug discovery
and development program, with diverse clinical trials, to allow therapeutics to be
evaluated and developed rapidly in response to COVID-19 and other pandemic threats.
This includes promoting the immediate and rapid development of therapeutics that
respond to COVID-19 by developing new antivirals directed against the coronavirus
family, accelerating research and support for clinical trials for therapeutics in response
to COVID-19 with a focus on those that can be readily scaled and administered, and
developing broad-spectrum antivirals to prevent future viral pandemics.
Promote immediate and rapid development of therapeutics that
respond to COVID-19.
The United States will immediately accelerate
research and support for clinical trials for therapeutics in response to
COVID-19 with a focus on those that can be readily scaled and administered.
To do so, the federal government will establish a comprehensive, integrated,
and coordinated preclinical drug discovery and development program, with
diverse clinical trials, to facilitate the rapid evaluation and development of
therapeutics in response to COVID-19 and other future pandemic threats.
As
part of this program, the federal government will stand up a program to develop
antivirals directed against the coronavirus family. By identifying targets (such
as proteases and polymerases) that are common to all members of this virus
family—which includes SARS, MERS, and SARS-CoV-2—broad-spectrum drug
therapies can be developed and tested under a more expedited time frame.
and Pandemic Preparedness
January 21, 2021
www.google.com/imgres?imgurl=https%3A%2F%2Fnlminfocusdotcom.files.wordpress.com%2F2014%2F11%2F761-fauci_schinazi.jpg%3Fw%3D700&imgrefurl=https%3A%2F%2Finfocus.nlm.nih.gov%2F2013%2F11%2F01%2Fcelebrating_public_service_at%2F&tbnid=aoztRpTDMyshIM&vet=12ahUKEwih7r7y9rLuAhVF66wKHQ-FBjEQMygAegQIARAZ..i&docid=x93Ncg9e3APY8M&w=250&h=209&q=Dr%20fauci%20and%20Dr%20Ray%20Schinazi&ved=2ahUKEwih7r7y9rLuAhVF66wKHQ-FBjEQMygAegQIARAZ
Raymond F. Schinazi, PhD, ScD (right) and Anthony S. Fauci, MD
Note: Very good chance COCP will be a very big part of this IMHO
www.whitehouse.gov/wp-content/uploads/2021/01/National-Strategy-for-the-COVID-19-Response-and-Pandemic-Preparedness.pdf
Prioritize therapeutics and establish a comprehensive, integrated
COVID-19 treatment discovery and development program.
Effective
treatments for COVID-19 are critical to saving lives. The federal government will
establish a comprehensive, integrated, and coordinated preclinical drug discovery
and development program, with diverse clinical trials, to allow therapeutics to be
evaluated and developed rapidly in response to COVID-19 and other pandemic threats.
This includes promoting the immediate and rapid development of therapeutics that
respond to COVID-19 by developing new antivirals directed against the coronavirus
family, accelerating research and support for clinical trials for therapeutics in response
to COVID-19 with a focus on those that can be readily scaled and administered, and
developing broad-spectrum antivirals to prevent future viral pandemics.
Promote immediate and rapid development of therapeutics that
respond to COVID-19.
The United States will immediately accelerate
research and support for clinical trials for therapeutics in response to
COVID-19 with a focus on those that can be readily scaled and administered.
To do so, the federal government will establish a comprehensive, integrated,
and coordinated preclinical drug discovery and development program, with
diverse clinical trials, to facilitate the rapid evaluation and development of
therapeutics in response to COVID-19 and other future pandemic threats.
As
part of this program, the federal government will stand up a program to develop
antivirals directed against the coronavirus family. By identifying targets (such
as proteases and polymerases) that are common to all members of this virus
family—which includes SARS, MERS, and SARS-CoV-2—broad-spectrum drug
therapies can be developed and tested under a more expedited time frame.